Basic Science
By: Marc G. Ghany, MD
|
Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection
Date Posted: 6/25/2008
|
|
Nearly one half of chronic hepatitis B patients from Indian cohort shown to be insulin resistant
Date Posted: 4/29/2008
|
By: Harvey Alter, MD
|
Harvey J. Alter, MD, MACP, discusses the top findings in viral hepatitis for the year 2007.
Date Posted: 8/6/2007
|
By: Adrian M. Di Bisceglie, MD, FACP, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, Daniel Shouval, MD
|
Adrian M. Di Bisceglie, MD, FACP; Geoffrey M. Dusheiko, MD, FCP(SA), FRCP; and Daniel Shouval, MD, discuss important clinical data presented on patients with chronic hepatitis B virus infection at the 2007 Annual Meeting of the European Association for the Study of the Liver.
Date Posted: 6/27/2007
|
|
The FibroTest and FibroScan noninvasive techniques for monitoring liver fibrosis can consistently exclude significant fibrosis in most inactive HBV carriers, for whom liver biopsy is contraindicated.
Date Posted: 10/31/2006
|
By: Stephen Locarnini, MD, PhD, FRC (Path)
|
Dr. Stephen Locarnini reviews the various uses of DNA as an indicator of disease activity and as a prognostic marker in HBV infection
Date Posted: 4/19/2006
|
By: Jean-Michel Pawlotsky, MD, PhD
|
Dr. Jean-Michel Pawlotsky reviews current definitions of HBV treatment failure and resistance
Date Posted: 4/19/2006
|
|
In vitro data suggest that dendritic cells carrying adenoassociated virus with HBV genes may provide a new immunotherapeutic strategy for the treatment of chronic hepatitis B.
Date Posted: 3/30/2006
|
|
Using RNA interference, Ye and colleagues demonstrated that HBx silencing reduces the proliferative effects of HBx protein, introducing a potential new gene therapy strategy for the reduction of HCC development in HBV-infected patients.
Date Posted: 3/29/2006
|
 |
File Format: Microsoft PowerPoint (.ppt) | File Size: 468 KB
Date Posted: 10/20/2005
|
|
Featured Content
Review a module and Interactive Case Challenge and use the new HBV DNA monitoring tool.
Join our experts as they review treatment options for patients with nonresponse to HCV therapy.
Expert faculty members review the most important advances in hepatitis and its mgmt in 2008.
|
|